Related Experiment Video
Updated: Jun 30, 2026
Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines
Published on: June 2, 2018
LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression
Jue Zhu1,2, Xinxin Xu1, Tiantian Li1
1Department of Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Abstract:
Endometriosis, a prevalent gynecological disease affecting women's health, involves altered immune function. This study investigates the immune checkpoint protein, V-domain immunoglobulin suppressor of T cell activation (VISTA) as a therapeutic target. In patient lesions, elevated VISTA expression correlated with reduced CD8+ T cell abundance. Using a 3D primary cell model, the research linked this immune suppression to a high-estrogen microenvironment and mast cell infiltration. Mechanistically, mast cell-derived LINC00632 cooperated with ERα to drive VISTA overexpression. A liposomal drug delivery system co-targeting estrogen signaling and LINC00632 successfully reduced VISTA levels, rescued CD8+ T cell function, and significantly inhibited lesion growth in a mouse model. This work elucidates a multicellular mechanism of immune evasion in endometriosis and demonstrates a promising combination therapeutic strategy.
Insights
Researchers identified V-domain immunoglobulin suppressor of T cell activation (VISTA) as a key factor in endometriosis immune evasion. Targeting estrogen and LINC00632 with a novel drug delivery system effectively reduced VISTA and inhibited lesion growth.
Area of Science:
- Immunology
- Gynecology
- Oncology
Background:
- Endometriosis is a common gynecological condition characterized by altered immune function.
- Immune evasion is a critical aspect of endometriosis progression.
- The immune checkpoint protein V-domain immunoglobulin suppressor of T cell activation (VISTA) has emerged as a potential therapeutic target.
Purpose of the Study:
- To investigate the role of VISTA in endometriosis-associated immune suppression.
- To elucidate the underlying molecular mechanisms driving VISTA overexpression in endometriosis.
- To develop and evaluate a novel combination therapeutic strategy targeting VISTA.
Main Methods:
- Analysis of VISTA expression and CD8+ T cell abundance in patient lesions.
- Utilizing a 3D primary cell model to study the effects of estrogen and mast cells on VISTA expression.
- Investigating the mechanistic link between mast cell-derived LINC00632, ERα, and VISTA.
- Developing and testing a liposomal drug delivery system for co-targeting estrogen signaling and LINC00632 in a mouse model of endometriosis.
Main Results:
- Elevated VISTA expression in endometriosis lesions correlated with decreased CD8+ T cell infiltration.
- A high-estrogen microenvironment and mast cell infiltration were linked to VISTA-mediated immune suppression.
- Mast cell-derived LINC00632 was found to cooperate with ERα to promote VISTA overexpression.
- The novel liposomal drug delivery system successfully reduced VISTA, restored CD8+ T cell function, and inhibited lesion growth in vivo.
Conclusions:
- This study uncovers a multicellular mechanism of immune evasion in endometriosis involving VISTA, estrogen, and mast cells.
- Targeting VISTA through combined inhibition of estrogen signaling and LINC00632 presents a promising therapeutic avenue for endometriosis.
- The developed liposomal drug delivery system demonstrates potential for effective treatment of endometriosis.
